Prognosis in<unk>  varies widely dependent upon disease type, stage, stem-cell source, HLA-matched status (for allogeneic<unk> , and conditioning regimen. A transplant offers a chance for cure or long-term remission if the inherent complications of graft versus host disease, immunosuppressive treatments and the spectrum of opportunistic infections can be survived. In recent years, survival rates have been gradually improving across almost all populations and subpopulations receiving transplants. Mortality for allogeneic stem cell transplantation can be estimated using the prediction model created by Sorror et al., using the<unk>  Cell Transplantation-Specific Comorbidity Index (HCT-CI). The HCT-CI was derived and validated by investigators at the Fred Hutchinson Cancer Research Center in the U.S. The HCT-CI modifies and adds to a well-validated comorbidity index, the Charlson comorbidity index (CCI) (Charlson, et al.) The CCI was previously applied to patients undergoing allogeneic HCT, but appears to provide less survival prediction and discrimination than the HCT-CI scoring system. Patients who were successfully treated with<unk>  and total body irradiation in childhood were found to have increased fat mass percentage, leading to significantly decreased exercise capacity in adulthood. This suggests patients who underwent successful treatment with<unk>  have an increased predisposition to cardiovascular disease later in life.
Hematopoietic stem cell transplantation
Syngeneic stem cell transplantation
Stem-cell therapy
Peripheral stem cell transplantation
Autologous stem-cell transplantation
Thymus transplantation
Autologous immune enhancement therapy
Spleen transplantation